

September 27, 2022  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Chimerix announces closing of brincidofovir sale to Emergent BioSolutions**

**TOKYO, Japan, September 27, 2022** -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or the "Company") today announced that Chimerix, Inc. (Headquarters: Durham, North Carolina, "Chimerix") announced in a press release dated September 26, 2022 (EST) that it has completed the closing of the sale of its antiviral product brincidofovir ("BCV") to Emergent BioSolutions Inc. (Headquarters: Gaithersburg, Maryland, "Emergent").

Please refer to Chimerix website for details of the press release.

<https://ir.chimerix.com/press-releases>

All rights and obligations of Chimerix under the license agreement between SymBio and Chimerix effective as of September 30, 2019 will be assigned to Emergent. The Company's exclusive worldwide development, manufacturing, and marketing rights for BCV for all indications except the prevention and treatment of orthopox infections will not be affected.

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2022.

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

**About Anti-viral Drug Brincidofovir**

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV.

**About Emergent BioSolutions Inc.**

Emergent BioSolutions Inc. (NYSE: EBS) is a pharmaceutical company based in Gaithersburg, Maryland, USA. The company develops vaccines and antibody drugs against infectious diseases and opioid overdose, and provides medical devices for biodefense. The company's mission is to protect and enrich lives, protecting people from things they hope will never happen and preparing them for the eventuality that they do happen for over 20 years. Through its portfolio of vaccines and therapeutics developed and manufactured for governments and consumers, the company provides solutions to complex and urgent public health threats. The company also provides comprehensive contract development and manufacturing services to pharmaceutical and biotechnology companies.

For more information, visit Emergent website at <https://www.emergentbiosolutions.com>).

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Carolyn Yanavich).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.